TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01153919

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: romiplostim
Description: Given subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Given orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG-interferon alfa-2a
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PEG-interferon alfa-2a
Description: Given subcutaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
Study: NCT03622567

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smartphone push notifications
Description: The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
Study: NCT02051296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: RCT blinded placebo trial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: RCT blinded placebo trial
Study: NCT03449251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relaxin
Description: Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: NO independent challenge agent

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LN Monomethyl arginine
Description: Basal NO synthase inhibitor
Study: NCT01258595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT01215188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Aluminum-adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Non-adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
Study: NCT03452930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Given IV
Study: NCT02643043

Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen Collection
Description: Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
Study: NCT03100487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple iPod Shuffle
Description: One session at least 5 days a week for a total of 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple iPod Shuffle
Description: One session at least 5 days a week for a total of 8 weeks
Study: NCT01548534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil.
Description: Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplementation with vegetable oil
Description: Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
Study: NCT04584632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efemoral Vascular Scaffold System (EVSS)
Description: Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
Study: NCT00359879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
Study: NCT00566085

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
Study: NCT00033280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02607631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: treated with Pembrolizumab 200 mg every 3 weeks
Study: NCT03900416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness App
Description: Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
Study: NCT02605655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-1915
Description: A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
Study: NCT00915590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Custom eye drop eye three times a day in both eyes for a period of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Custom eye drop eye three times a day in both eyes for a period of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Description: 5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Description: 5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
Study: NCT04836741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robot
Description: The surgeries are performed with the Micro Hand S robot

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscope
Description: The surgeries are performed with the laparoscope
Study: NCT04680832

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electronic nose
Description: First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow \<0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.
Study: NCT01225549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Suspension for nebulisation once daily 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Suspension for nebulisation once daily 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200 microgram
Description: Dry powder for inhalation twice daily 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days
Study: NCT00371735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorproguanil-dapsone-artesunate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorproguanil-dapsone
Study: NCT03101306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR scans
Description: Additional imaging using MR scans.
Study: NCT04974073

Intervention type: DRUG
Group type: OTHER
Intervention: PHY606
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Study: NCT02605655

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instant noodles without drug
Study: NCT03507777

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by OCT
Description: Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by Angiography
Description: Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
Study: NCT03507751

Intervention type: DRUG
Intervention: Meropenem
Description: 1.0 gram of meropenem given intravenously every 8 hours

Intervention type: DEVICE
Intervention: CRRT
Description: Continuous renal replacement therapy for three days
Study: NCT00473148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BNP-guided weaning
Description: BNP-guided weaning

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Standard physician-directed weaning
Description: Standard physician-directed weaning
Study: NCT02471105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preserved Bimatoprost 0.01%
Description: Eye drops solution Topical use Once in the evening 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preserved Bimatoprost 0.01%
Description: Eye drops solution Topical use Once in the evening 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost Unit Dose Preservative Free 15microgram/ml
Description: Eye drops solution Topical use Once in the evening 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost Unit Dose Preservative Free 15microgram/ml
Description: Eye drops solution Topical use Once in the evening 3 months
Study: NCT00992225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
Study: NCT03618043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
Study: NCT04974073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHY606
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Study: NCT01329198

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroPace RNS® System Deep Brain Stimulator
Description: Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroPace RNS® System Deep Brain Stimulator
Description: Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Study: NCT02349555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement Blend
Description: It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
Study: NCT03212716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 150 mg twice a day during 10 days (ANSM guidelines for severe flu).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 150 mg twice a day during 10 days (ANSM guidelines for severe flu).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 60 mgx3 per day during 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo of diltiazem
Study: NCT04327778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Automate music therapy every two weeks
Study: NCT03531866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News
Description: DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News
Description: DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
Study: NCT02068937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide and Phone contact
Description: The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
Study: NCT04595058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double pigtail plastic stent through lumen-apposing metal stent
Description: Biliary drainage guided by endoscopic ultrasound: Addition or not, of a axis-orienting plastic stent, mostly, double-pigtail stent through the lumen of a lumen-apposing metal stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lumen-apposing metal stent without double pigtail plastic stent
Description: Endoscopic ultrasound-guided transmural biliary drainage is with lumen-apposing metal stent is a formal indication according to the instruction forms of the manufacturer.
Study: NCT04418947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication type
Description: Control letter vs. intervention letter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication type
Description: Control letter vs. intervention letter

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication type
Description: Control letter vs. intervention letter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication type
Description: Control letter vs. intervention letter
Study: NCT04556760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567
Description: Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567
Description: Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 3 consecutive days of each treatment period in Cohort 3.
Study: NCT04654741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone Acetate
Description: 1 pill per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix Acetate
Description: 1 injection per day
Study: NCT03928457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental questionnaire
Description: Parental questionnaire on pregnancy history and environmental exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily continuous recording of radiofrequency exposure levels
Description: Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up of daily infants environmental and clinical parameters
Description: Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures...)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nocturnal polysomnography
Description: Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cerebral hemodynamics
Description: cerebral hemodynamics (near infrared spectroscopy)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: activity of the autonomic nervous system
Description: activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
Study: NCT00902655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
Study: NCT03348605

Intervention type: DEVICE
Group type: OTHER
Intervention: Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany
Description: This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole.

Intervention type: DEVICE
Group type: OTHER
Intervention: Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany
Description: This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole.